![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 0114-9954
Source: Reactions Weekly, Vol.1, Iss.1387, 2012-01, pp. : 3-3
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
EMEA reports ADR research priorities for 2010
Reactions Weekly, Vol. 1, Iss. 1266, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
MHRA receives further ADR reports with varenicline
Reactions Weekly, Vol. 1, Iss. 1228, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Patient ADR reports offer rich detail
Reactions Weekly, Vol. 1, Iss. 1353, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Eltroxin: ADR reports increase following excipient change
Reactions Weekly, Vol. 1, Iss. 1318, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Flu vaccine ADR reports increased in New Zealand
Reactions Weekly, Vol. 1, Iss. 1346, 2011-01 ,pp. :